Coeptis Therapeutics, Inc. (Coeptis), entered into a termination agreement with Statera Biopharma, Inc. (Statera), pursuant to which the previously announced strategic agreement with Statera related to Statera's toll-like receptor 5 (TLR5) agonist was terminated. Pursuant to the termination agreement, both parties acknowledged that neither party has any further obligations to the other under the terminated agreement. The termination was based on the mutual determination by both parties, and no termination penalties were incurred by Coeptis or Statera.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | +16.67% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 50.81K | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.98% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Coeptis Therapeutics, Inc. Enters into Termination Agreement with Statera Biopharma, Inc